Clinical Trial: Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06427694) titled 'Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study' on May 20.

Brief Summary: The preceding IVORY trial (NCT04241601) has completed. As atherosclerosis and its complications are driven by inflammation we hypothesise that treatment with low-dose IL2 may reduce adverse cardiovascular outcomes compared to placebo.

In this follow-up study, we aim to collect cardiovascular clinical outcome data for patients who completed the IVORY clinical trial and will look at major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction, resuscitated cardi...